Yuk Ting

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

John P. Neoptolemos, Daniel H. Palmer, Paula Ghaneh et al. · The Lancet · 2017 · 1.9K citations · Full text

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

John Primrose, Richard Fox, Daniel H. Palmer et al. · The Lancet Oncology · 2019 · 1.2K citations · Full text

Surgical Oncology, Gastrointestinal Oncology, Medicine +10

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

Ángela Lamarca, Daniel H. Palmer, Harpreet Wasan et al. · The Lancet Oncology · 2021 · 711 citations · Full text

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial

Tim Meyer, Richard Fox, Yuk Ting et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 482 citations · Full text

Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial

Paula Ghaneh, Daniel H. Palmer, Silvia Cicconi et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 294 citations · Full text

Surgical Oncology, Immediate Surgery, Pancreatic Cancer +7